甲氧苄啶/磺胺嘧啶 與 甲氧苄啶/磺胺甲噁唑
增效磺胺類藥物（常被稱為 TMS、SMZ-TMP 或 co-trimoxazole）是獸醫學中廣泛使用的廣效、殺菌性抗菌複合藥物。 **關鍵臨床要點：** - **優異的組織穿透力：** 具高脂溶性，能達到難以穿透的組織（如**前列腺**、**血腦屏障 (CNS)** 和**眼睛**）的治療濃度。 - **廣效性：** 對許多革蘭氏陽性與陰性菌有效，包含許多抗甲氧苯青黴素葡萄球菌 (MRSA/MRSP) 菌株、*諾卡氏菌*，以及某些原蟲（*弓形蟲*、*球蟲*、*肺囊蟲*）。 - **受膿液去活化：** 藥效會被化膿性碎屑和壞死組織（富含 PABA 和胸苷）顯著抑制。必須引流膿瘍才能發揮藥效。 - **品種敏感性：** 杜賓犬對磺胺類藥物誘發的多系統免疫複合體疾病（過敏反應）具有已知的品種特異性易感性。 - **劑型：** 雖然有獸醫核准的甲氧苄啶/磺胺嘧啶產品，但許多獸醫師也會以仿單標示外使用 (off-label use) 的方式，使用人類核准的甲氧苄啶/磺胺甲噁唑 (Bactrim®, Septra®)，且療效相似。
作用機制: Potentiated sulfas exhibit **synergistic, bactericidal** activity by sequentially blocking the bacterial folic acid synthesis pathway. Mammalian cells are largely unaffected because they utilize preformed dietary folate rather than synthesizing it. - **Sulfonamides (Bacteriostatic alone):** Act as structural analogues of para-aminobenzoic acid (PABA). They competitively inhibit the bacterial enzyme **dihydropteroate synthase** → blocks the conversion of PABA to dihydrofolic acid (DFA). - **Trimethoprim (Bactericidal alone):** Reversibly inhibits the bacterial enzyme **dihydrofolate reductase** → blocks the conversion of DFA to tetrahydrofolic acid (THFA). - **Synergy:** The sequential blockade completely depletes THFA, an essential cofactor for bacterial DNA and RNA synthesis, leading to rapid bacterial cell death. > *Pharmacologic Note:* The optimal *in vitro* ratio for most susceptible bacteria is 1:20 (trimethoprim:sulfa), but synergistic activity occurs across a wide range (1:1 to 1:40). The serum concentration of the trimethoprim component is generally considered the primary driver of efficacy.
各物種劑量
- UTI · 30 mg/kg PO q24h · PO · q24h · 7-14 days
- UTI, soft tissue infections · 15 mg/kg PO q12h · PO · q12h · 7-14 days
- Susceptible infections · 30 mg/kg q12h · PO · q12h · If treating Nocardia, double dose
- Toxoplasmosis · 15 mg/kg PO q12h · PO · q12h · 28 days
- Bacterial UTI · 30 mg/kg q12h PO · PO · q12h
- Susceptible infections · 30 mg/kg PO twice daily · PO · q12h
- Coccidiosis · 30 mg/kg PO once daily · PO · q24h · 14 days
- Susceptible infections · 44 mg/kg once daily IM or IV using 48% suspension · IM/IV · q24h
- Susceptible infections · 25 mg/kg, IV or IM q24h · IV/IM · q24h
- Susceptible infections (Calves) · 48 mg/kg IV or IM q24h · IV/IM · q24h
- Respiratory tract infections · 15-30 mg/kg PO q12h · PO · q12h · Give 30 minutes prior to feeding hay
給藥途徑
禁忌症
- Hypersensitivity to sulfonamides, thiazides, or sulfonylurea agents
- Severe renal or hepatic impairment
- Doberman pinschers (highly susceptible to immune complex disease)
- Marked blood dyscrasias
- Animals intended for food (in the USA/certain jurisdictions)
不良反應
- Dogs: Keratoconjunctivitis sicca (KCS/dry eye - potentially irreversible)
- Dogs: Hypersensitivity reactions (Type 1 anaphylaxis or Type 3 serum sickness, polyarthritis, urticaria, facial swelling)
- Dogs: Acute neutrophilic hepatitis with icterus, idiosyncratic hepatic necrosis
- Dogs: Vomiting, anorexia, diarrhea
- Dogs: Hemolytic anemia, agranulocytosis
- Dogs: Hypothyroidism (with extended therapy)
- Dogs: Crystalluria, hematuria, polyuria, polydipsia
- Cats: Anorexia, crystalluria, hematuria, leukopenias, anemias
- Horses: Transient pruritus (after IV injection), diarrhea, hypersensitivity, hematologic effects
- Injection site reactions: Swelling, pain, tissue damage (IM, SC, or extravasation)
藥物相互作用
- Amantadine · May cause toxic delirium (reported in humans)
- Antacids · May decrease the bioavailability of sulfonamides if administered concurrently
- Cyclosporine · May increase the risk of nephrotoxicity
- Digoxin · May increase digoxin levels
- Diuretics, Thiazide · May increase risk for thrombocytopenia
- Hypoglycemic agents, oral · May potentiate hypoglycemic effects
- Methotrexate · May displace from plasma proteins and increase risk for toxic effects; can also interfere with MTX assays
- Phenytoin · May increase half-life of phenytoin
- Tricyclic antidepressants · May decrease efficacy of the antidepressant
- Warfarin · May prolong INR/PT and increase bleeding risk
監測
- Clinical efficacy
- Adverse effects (GI, hypersensitivity)
- Complete blood counts (CBC) periodically with chronic therapy
- Schirmer Tear Test (STT) in dogs to monitor tear production (e.g., at 5 days, then every 2-3 weeks)
- Thyroid function tests (baseline and ongoing) for dogs on long-term treatment
過量
Manifestations of acute overdosage include GI distress (nausea, vomiting, diarrhea), CNS toxicity (depression, headache, confusion), facial swelling, bone marrow depression, and elevated serum aminotransferases. **Treatment:** - **Oral Overdose:** Empty the stomach following usual protocols and initiate symptomatic/supportive therapy. - **Fluid Therapy:** Maintain hydration. Acidification of urine may increase renal elimination of trimethoprim but increases the risk of sulfonamide crystalluria (especially with sulfadiazine). - **Monitoring:** Monitor complete blood counts and liver parameters. - **Bone Marrow Suppression:** If severe and associated with chronic overdose, may be treated with folinic acid (leucovorin). - *Note:* Peritoneal dialysis is not effective in removing TMP or sulfas from circulation.
VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用,不能取代專業判斷或廠方最新藥品說明書。